Kanabo’s CBD Based "Smoking Cessation" Formula Moves One Step Closer to Full Patent Approval
15 Diciembre 2021 - 12:45AM
Business Wire
- Global smoking cessation market expected
to reach £50m ($64m) by 2026 -
- Smoking and e-cigarette addiction could be
beat, easing pressure on health services globally -
Kanabo, one of Europe’s fastest-growing medical cannabis and
R&D companies that focuses on the distribution of
cannabis-derived products for medical patients, and wellness CBD
consumers, today announced that its unique CBD and nicotine formula
has moved from Patent Cooperation Treaty (PCT) phase to National
Phase in the US, UK, and EU countries - the last phase before
becoming an internationally approved patent.
Targeted at people wanting to quit both traditional smoking and
their e-cigarettes is a huge market that is expected to reach £50m
within a few years. Kanabo’s unique, high potency CBD and nicotine
and standalone CBD formulas, delivered by their proprietary
cartridges and VapePod, can be used to treat nicotine and tobacco
addiction, with evidence so far suggesting the programme
significantly reduces physical and psychological nicotine
withdrawal effects.
Covered under the Kanabo patent application is the unique new
formula development of specific naturally derived terpenes to allow
the application of a very consistent and reproducible, high
concentration of CBD throughout the life of the Kanabo cartridge.
Initially, CBD is combined with Nicotine, which is then reduced
over several weeks until there is zero Nicotine presence.
Tests with a handful of volunteers who smoke, that participated
in Kanabo’s trial, have presented an average reduction of 70 per
cent in their cigarette consumption and did not experience physical
or psychological withdrawal effects
As countries worldwide continue to seek measures to reduce
tobacco smoking and even ban the use of tobacco products*, Kanabo’s
new IP offers a novel and effective way to reduce smoking and
potentially complete withdrawal from Nicotine and e-cigarette
addiction.
Avihu Tamir, CEO Kanabo, said, "Our unique patent pending CBD
formulations and controlled and consistent delivery device, the
VapePod, represents an excellent opportunity for governments to
quickly end the reliance on tobacco for millions of citizens
worldwide. Our tests show a dramatic reduction in nicotine
consumption, whether in cigarettes or e-cigarettes, which can only
be good news for health services around the world."
Note to editor: *
https://www.bbc.com/news/world-asia-59589775
About Kanabo Group Plc
Kanabo Group Plc is an R&D company currently selling a range
of THC-Free Retail CBD Products in the Primary Markets and is in
the process of developing further Medical Cannabis Products. The
company’s core strategy is to increase revenues from the sale of
its Retail CBD Products in the wellness sector and to grow the
Kanabo brand through its marketing initiatives.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211214006310/en/
Dan Walsh dan@mustardpr.com
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024